Absorbable Fibrin Sealant Patch Market By Application (General Surgery , Cardiovascular Surgery , Wound Management , Orthopedic Surgery , Urological Surgery, Ophthalmic Surgery, Others) , By End User (Hospitals and Clinics , Ambulatory Surgical Centers , Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Absorbable Fibrin Sealant Patch Market
The absorbable fibrin sealant patch market was valued at $0.3 billion in 2023 and is projected t%li%reach $0.7 billion by 2033, growing at a CAGR of 7.8% from 2024 t%li%2033.
An absorbable fibrin sealant patch is a sterile object used in surgical procedures t%li%control bleeding and promote tissue healing. It is a biodegradable patch comprising of equine collagen sponge along with fibrinogen and thrombin, elements which are the key players in the natural blood clotting mechanism of the body. The formulation of the patch involves absorption by the body over time, hence eradicating the need for removal and reducing the risk of infections. The sealant patch is significantly administered during surgeries in which conventional stapling or suturing is difficult or insufficient for hemostasis.
Rise in the conduction of surgical procedures across the globe due t%li%increase in prevalence of cardiovascular, orthopedic, and general health complications is a key driver of the absorbable fibrin sealant patch market. Moreover, surge in the popularity of minimally invasive operations is boosting the adoption of sealant patches as they eliminate the post-recovery intricacies. As an emerging trend, sealant patches that are equally active and effective on both sides are acquiring traction. When compared t%li%the conventional patches, the new sealant patches are reported t%li%be quick by an average of six times, ceasing bleeding in 30 minutes.
However, the cost of surgical procedures involving the use of sealant patches is significantly high as compared t%li%the traditional surgeries, which deters several individuals from preferring them. This acts a major restraint for the absorbable fibrin sealant patch market. On the contrary, constant advancements in sealant patches are expected t%li%present lucrative opportunities for market expansion. According t%li%a study published in Nature, a British scientific journal, next generation of patches are being designed that are projected t%li%provide instant adhesion, possess compatibility with rapid photo-projection, and have the potential t%li%deliver therapeutics.
Segment Review
The absorbable fibrin sealant patch market is segmented int%li%application, end user, and region. On the basis of application, the market is divided int%li%general surgery, cardiovascular surgery, wound management, orthopedic surgery, urological surgery, ophthalmic surgery, and others. As per end user, it is classified int%li%hospitals & clinics, ambulatory surgical centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of application, the others segment dominates the absorbable fibrin sealant patch market.
As per end user, the hospitals & clinics segment holds a high share of the market.
Region wise, North America is projected t%li%be the highest revenue generator by 2033.
Competition Analysis
The major players operating in the global absorbable fibrin sealant patch market include Johnson & Johnson, Baxter International Inc, Takeda Pharmaceutical Company Limited, Becton, Dickinson and Company, Corza Medical, LifeBond Ltd, Surgical Specialties Corporation, Biegler GmbH, Cohera Medical Inc, and Integra LifeSciences Corporation. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships t%li%strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
By Application
The absorbable fibrin sealant patch market was valued at $0.3 billion in 2023 and is projected t%li%reach $0.7 billion by 2033, growing at a CAGR of 7.8% from 2024 t%li%2033.
An absorbable fibrin sealant patch is a sterile object used in surgical procedures t%li%control bleeding and promote tissue healing. It is a biodegradable patch comprising of equine collagen sponge along with fibrinogen and thrombin, elements which are the key players in the natural blood clotting mechanism of the body. The formulation of the patch involves absorption by the body over time, hence eradicating the need for removal and reducing the risk of infections. The sealant patch is significantly administered during surgeries in which conventional stapling or suturing is difficult or insufficient for hemostasis.
Rise in the conduction of surgical procedures across the globe due t%li%increase in prevalence of cardiovascular, orthopedic, and general health complications is a key driver of the absorbable fibrin sealant patch market. Moreover, surge in the popularity of minimally invasive operations is boosting the adoption of sealant patches as they eliminate the post-recovery intricacies. As an emerging trend, sealant patches that are equally active and effective on both sides are acquiring traction. When compared t%li%the conventional patches, the new sealant patches are reported t%li%be quick by an average of six times, ceasing bleeding in 30 minutes.
However, the cost of surgical procedures involving the use of sealant patches is significantly high as compared t%li%the traditional surgeries, which deters several individuals from preferring them. This acts a major restraint for the absorbable fibrin sealant patch market. On the contrary, constant advancements in sealant patches are expected t%li%present lucrative opportunities for market expansion. According t%li%a study published in Nature, a British scientific journal, next generation of patches are being designed that are projected t%li%provide instant adhesion, possess compatibility with rapid photo-projection, and have the potential t%li%deliver therapeutics.
Segment Review
The absorbable fibrin sealant patch market is segmented int%li%application, end user, and region. On the basis of application, the market is divided int%li%general surgery, cardiovascular surgery, wound management, orthopedic surgery, urological surgery, ophthalmic surgery, and others. As per end user, it is classified int%li%hospitals & clinics, ambulatory surgical centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of application, the others segment dominates the absorbable fibrin sealant patch market.
As per end user, the hospitals & clinics segment holds a high share of the market.
Region wise, North America is projected t%li%be the highest revenue generator by 2033.
Competition Analysis
The major players operating in the global absorbable fibrin sealant patch market include Johnson & Johnson, Baxter International Inc, Takeda Pharmaceutical Company Limited, Becton, Dickinson and Company, Corza Medical, LifeBond Ltd, Surgical Specialties Corporation, Biegler GmbH, Cohera Medical Inc, and Integra LifeSciences Corporation. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships t%li%strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
By Application
- General Surgery
- Cardiovascular Surgery
- Wound Management
- Orthopedic Surgery
- Urological Surgery
- Ophthalmic Surgery
- Others
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Johnson & Johnson
- Baxter International Inc
- Takeda Pharmaceutical Company Limited
- Becton, Dickinson and Company.
- Corza Medical
- LifeBond Ltd
- Surgical Specialties Corporation
- Biegler GmbH
- Cohera Medical Inc
- Integra LifeSciences Corporation
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, BY TECHNOLOGY
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology
4.2. Computed Tomography
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Magnetic Resonance Imaging
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Carotid Ultrasound
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Cerebral Angiography
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Electrocardiography
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
4.7. Echocardiography
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, By Region
4.7.3. Market Share Analysis, By Country
4.8. Others
4.8.1. Key Market Trends, Growth Factors and Opportunities
4.8.2. Market Size and Forecast, By Region
4.8.3. Market Share Analysis, By Country
CHAPTER 5: ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals And Clinics
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Ambulatory Surgery Centers
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Diagnostic Laboratories And Imaging Centers
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Others
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Technology
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Acute Ischemic Stroke Diagnosis Market
6.2.5.1. Market Size and Forecast, By Technology
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Acute Ischemic Stroke Diagnosis Market
6.2.6.1. Market Size and Forecast, By Technology
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Acute Ischemic Stroke Diagnosis Market
6.2.7.1. Market Size and Forecast, By Technology
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Technology
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Acute Ischemic Stroke Diagnosis Market
6.3.5.1. Market Size and Forecast, By Technology
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Acute Ischemic Stroke Diagnosis Market
6.3.6.1. Market Size and Forecast, By Technology
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Acute Ischemic Stroke Diagnosis Market
6.3.7.1. Market Size and Forecast, By Technology
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Acute Ischemic Stroke Diagnosis Market
6.3.8.1. Market Size and Forecast, By Technology
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Acute Ischemic Stroke Diagnosis Market
6.3.9.1. Market Size and Forecast, By Technology
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Acute Ischemic Stroke Diagnosis Market
6.3.10.1. Market Size and Forecast, By Technology
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Technology
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Acute Ischemic Stroke Diagnosis Market
6.4.5.1. Market Size and Forecast, By Technology
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Acute Ischemic Stroke Diagnosis Market
6.4.6.1. Market Size and Forecast, By Technology
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Acute Ischemic Stroke Diagnosis Market
6.4.7.1. Market Size and Forecast, By Technology
6.4.7.2. Market Size and Forecast, By End User
6.4.8. Australia Acute Ischemic Stroke Diagnosis Market
6.4.8.1. Market Size and Forecast, By Technology
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Acute Ischemic Stroke Diagnosis Market
6.4.9.1. Market Size and Forecast, By Technology
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Acute Ischemic Stroke Diagnosis Market
6.4.10.1. Market Size and Forecast, By Technology
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Technology
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Acute Ischemic Stroke Diagnosis Market
6.5.5.1. Market Size and Forecast, By Technology
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Acute Ischemic Stroke Diagnosis Market
6.5.6.1. Market Size and Forecast, By Technology
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Acute Ischemic Stroke Diagnosis Market
6.5.7.1. Market Size and Forecast, By Technology
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Acute Ischemic Stroke Diagnosis Market
6.5.8.1. Market Size and Forecast, By Technology
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Koninklijke Philips N.V.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. GE Healthcare
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Canon Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Simens
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Terumo Corporation
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Stryker
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Fujifilm Holdings Corporation
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Samsung Electronics Co. Ltd
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. F. Hoffmann-La Roche Ltd
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Boehringer Ingelheim International GmbH
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, BY TECHNOLOGY
4.1. Market Overview
4.1.1 Market Size and Forecast, By Technology
4.2. Computed Tomography
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Magnetic Resonance Imaging
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Carotid Ultrasound
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Cerebral Angiography
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
4.6. Electrocardiography
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, By Region
4.6.3. Market Share Analysis, By Country
4.7. Echocardiography
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, By Region
4.7.3. Market Share Analysis, By Country
4.8. Others
4.8.1. Key Market Trends, Growth Factors and Opportunities
4.8.2. Market Size and Forecast, By Region
4.8.3. Market Share Analysis, By Country
CHAPTER 5: ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals And Clinics
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Ambulatory Surgery Centers
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Diagnostic Laboratories And Imaging Centers
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Others
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Technology
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Acute Ischemic Stroke Diagnosis Market
6.2.5.1. Market Size and Forecast, By Technology
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Acute Ischemic Stroke Diagnosis Market
6.2.6.1. Market Size and Forecast, By Technology
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Acute Ischemic Stroke Diagnosis Market
6.2.7.1. Market Size and Forecast, By Technology
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Technology
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Acute Ischemic Stroke Diagnosis Market
6.3.5.1. Market Size and Forecast, By Technology
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Acute Ischemic Stroke Diagnosis Market
6.3.6.1. Market Size and Forecast, By Technology
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Acute Ischemic Stroke Diagnosis Market
6.3.7.1. Market Size and Forecast, By Technology
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Acute Ischemic Stroke Diagnosis Market
6.3.8.1. Market Size and Forecast, By Technology
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Acute Ischemic Stroke Diagnosis Market
6.3.9.1. Market Size and Forecast, By Technology
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Acute Ischemic Stroke Diagnosis Market
6.3.10.1. Market Size and Forecast, By Technology
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Technology
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Acute Ischemic Stroke Diagnosis Market
6.4.5.1. Market Size and Forecast, By Technology
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Acute Ischemic Stroke Diagnosis Market
6.4.6.1. Market Size and Forecast, By Technology
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Acute Ischemic Stroke Diagnosis Market
6.4.7.1. Market Size and Forecast, By Technology
6.4.7.2. Market Size and Forecast, By End User
6.4.8. Australia Acute Ischemic Stroke Diagnosis Market
6.4.8.1. Market Size and Forecast, By Technology
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Acute Ischemic Stroke Diagnosis Market
6.4.9.1. Market Size and Forecast, By Technology
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Acute Ischemic Stroke Diagnosis Market
6.4.10.1. Market Size and Forecast, By Technology
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Technology
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Acute Ischemic Stroke Diagnosis Market
6.5.5.1. Market Size and Forecast, By Technology
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Acute Ischemic Stroke Diagnosis Market
6.5.6.1. Market Size and Forecast, By Technology
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Acute Ischemic Stroke Diagnosis Market
6.5.7.1. Market Size and Forecast, By Technology
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Acute Ischemic Stroke Diagnosis Market
6.5.8.1. Market Size and Forecast, By Technology
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Koninklijke Philips N.V.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. GE Healthcare
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Canon Inc.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Simens
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Terumo Corporation
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Stryker
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Fujifilm Holdings Corporation
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Samsung Electronics Co. Ltd
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. F. Hoffmann-La Roche Ltd
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Boehringer Ingelheim International GmbH
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
